Highlights
- Elinzanetant is a first-in-class, non-hormonal small molecule antagonist targeting neurokinin 1 and 3 receptors (NK1 and NK3), developed by Bayer for vasomotor symptoms (VMS) of menopause.
- In July 2025, it was approved in the United Kingdom, followed by FDA approval in October 2025 for moderate-to-severe menopausal VMS, marking a major advance in menopause management.
- Robust evidence from phase 2b and pivotal phase 3 trials (SWITCH-1 and OASIS 1/2) demonstrated statistically significant reductions in VMS frequency and severity, along with improvements in sleep disturbances and quality of life.
- Mechanistic studies confirm elinzanetant’s dose-dependent suppression of reproductive hormone levels (estradiol, progesterone) without inducing vasomotor symptoms in healthy women, supporting its novel pharmacological profile.
Background
Specialty calculators
For clinical reference; use professional judgment.
